Nebenwirkungen · Cinqaero
CINQAERO 10 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 6
HOS-132907 · Präparat HOS-097318
The following adverse reactions have been reported with reslizumab during placebo-controlled asthma studies for up to 52 weeks of treatment with a 3 mg/kg dose given intravenously. Adverse reactions are listed below in Table 2 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T17:10:00Z · SHA-256 f212e389997963271e96173c7da28e17f5a0e78b0df699519e7f56e8e9277a73 · Passage 4d94301398764f1b9703d8afd5cd36fa0aff4e1d016b0f808f3cf74561ad221f · Zeichen 430–910 im Abschnitt